



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Journal Pre-proof

Fighting stigma and discrimination against COVID-19 in China

Ming Zheng

PII: S1198-743X(22)00546-8

DOI: <https://doi.org/10.1016/j.cmi.2022.10.032>

Reference: CMI 3117

To appear in: *Clinical Microbiology and Infection*

Received Date: 30 September 2022


Revised Date: 28 October 2022

Accepted Date: 31 October 2022

Please cite this article as: Zheng M, Fighting stigma and discrimination against COVID-19 in China, *Clinical Microbiology and Infection*, <https://doi.org/10.1016/j.cmi.2022.10.032>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2022 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.



1 **Commentary**

2
3
4 **Fighting stigma and discrimination against COVID-19 in China**

5
6 Ming Zheng^{1,2,*}

7
8 **Authors' Affiliations:**

9 1. Institute of Military Cognition and Brain Sciences, Academy of Military Medical
10 Sciences, 27 Taiping Road, Beijing 100850, China

11 2. Beijing Institute of Basic Medical Sciences, 27 Taiping Road, Beijing 100850, China

12 * Corresponding author.

13
14
15 Correspondence to: **Ming Zheng, MD, Ph.D.**, Institute of Military Cognition and Brain
16 Sciences, Academy of Military Medical Sciences, 27 Taiping Road, Beijing 100850,
17 China (E-mail: mmzheng@fmmu.edu.cn or zhengming_china@163.com;

18 ORCID ID: <https://orcid.org/0000-0002-3651-7701>;

19 Researcher ID: <https://publons.com/researcher/4413823/ming-zheng>).

20
21 **running title:** Fighting discrimination against COVID-19

22
23 **Word counts:** 1327 words (main text)

24 **Reference counts:** 10 references

26

27 Stigma and discrimination against COVID-19

28 As of October 28, 2022, there were 634,725,675 confirmed cases and 6,589,734
29 deaths attributed to COVID-19 (<https://www.worldometers.info/coronavirus/>)
30 worldwide. Around 614 million COVID-19 patients have recovered, and more patients
31 will return home and work after recovery. In China, recovered COVID-19 patients have
32 frequently suffered stigma and discrimination in daily life and at work. In a quantitative
33 study of 2377 participants in China, 79.76% of the participants displayed discrimination
34 against recovered COVID-19 patients.[1] In the early stage of the pandemic, COVID-19
35 survivors were not allowed to enter public places, including restaurants, shops, and public
36 transports. Afterwards, they often faced discrimination in other spheres, including health-
37 related insurance, renting houses, and even job promotion. Recently, "no positive
38 COVID-19 history" is often required in Chinese labor market.[2] People with a previous
39 history of COVID-19 infection are unable to socialize normally and may face bankruptcy.

40 Since the COVID-19 pandemic, such stigma and discrimination have been
41 experienced by patients with or recovered from symptomatic and asymptomatic
42 infections, and even expanded to close contacts and suspected cases.[3] In a quantitative
43 survey study of 7,942 Chinese participants, people residing in the epicenters of COVID-
44 19 outbreak reported greater stigmatization and perceived discrimination than those in
45 no-COVID-19 regions; the stigmatization and discrimination were also higher in people
46 socially associated with COVID-19 outbreak area.[4] According to several domestic
47 studies in China, COVID-19-related stigma and discrimination could significantly impair
48 people's mental health and well-being, not only in patients discharged from hospital [5,
49 6] but also in people geographically or socially associated with COVID-19 outbreaks.[4]

50

51

52 The loop of fear and discrimination

53 The COVID-19 pandemic has created widespread fear. Fear is a key ingredient for
54 discrimination to thrive. COVID-19-related discrimination not only harms the rights and
55 dignity of innocent people, but also hinders the control and treatment of the disease.

56 When the disease is associated with discrimination, the patients are more inclined to
57 conceal their infection to avoid unfair discrimination. The unreported infections will
58 make the epidemic more difficult to manage, hampering the efforts of controlling disease
59 spread.[7] Additionally, early treatment could reduce disease severity and prevent the
60 long-lasting sequela of COVID-19.[8] Concealing disease will delay early treatment,
61 causing severe negative consequences. The strength of our health system in disease
62 control and treatment is inseparable from social inclusion, tolerance, solidarity, and
63 justice. Without these key factors, discrimination will continuously deepen the fear of
64 the disease, which in turn magnifies the discrimination.

65

66

67 **Fighting COVID-19-related fear and discrimination**

68 The world has seen pandemics and epidemics for centuries. The fear and
69 discrimination against contagious diseases are nothing new in human history. In the
70 modern era of medicine, with effective prevention and treatment of disease, this
71 instinctive fear and discrimination could gradually fade and eventually disappear.

72 In China, a “dynamic zero-COVID” policy was adopted with massive viral testing,
73 universal vaccination, and strict quarantine of COVID-19 patients.[9] After recovered
74 patients were discharged from the hospital, the Chinese National Health Commission
75 recommended continuing health monitoring for seven days as a precaution.[10] The
76 recovered COVID-19 patients will generally not be infected again in a short period of
77 time, nor will they cause a threat to the public.

78 The COVID-19-related discrimination highlights the poor knowledge and
79 misconceptions about the disease. Therefore, public education should play a critical part
80 in fighting discrimination. Here, we call on public media to provide sufficient and
81 accurate scientific information about COVID-19 to help eliminate COVID-19
82 discrimination. Additionally, COVID-19-related inflammatory rhetoric and scapegoating
83 should not be allowed. After all, when COVID-19 patients return from recovery, what
84 they need most is understanding and fair interpersonal treatment in daily life and at work.

85

86

87 Refractory fear and discrimination due to socio-economic inequality

88 Under China's adherence to the “dynamic zero-COVID” policy, viral transmission
89 is controlled in a minimum range of very few COVID-19 patients and sporadic
90 asymptomatic infections.[9] However, fear and discrimination still prevail, which have
91 expanded to close contacts, secondary close contacts, and even family members of
92 COVID-19 patients. This kind of fear and discrimination is refractory due to its complex
93 overlapping with social and economic inequalities. The pandemic disproportionately
94 imposes a heavy socio-economic burden on people with a higher likelihood of viral
95 exposure, including those—to name a few—working in an essential service that requires
96 close contact with others, living in overcrowded houses with poor air ventilation, or
97 living in neighborhoods with poor hygienic conditions. The COVID-19 pandemic
98 exacerbates socio-economic inequality in housing, labor markets, and access to health
99 services. Therefore, the above-stated fear and discrimination did not emerge simply as a
100 result of the pandemic, but also due to socio-economic inequality.

101 In response to growing COVID-19 outbreaks, China has continuously revised the
102 COVID-19 diagnosis and treatment guidelines in nine editions. In the latest 9th edition of
103 isolation and discharge criteria, the precaution after discharge has changed from 14-days
104 quarantine to 7-days health monitoring at home,[10] showing a sign of China’s initiative
105 to explore anti-COVID-19 policies with minimal socio-economic cost. On October 16,
106 2022, the 20th National Congress meeting of China was held, and a national agenda of
107 fighting COVID-19 was proposed to coordinate anti-COVID-19 policies with social and
108 economic development, aiming to strike a balance between socio-economic benefits and
109 people’s health.

110

111

112 Emerging legal and ethical challenges

113 COVID-19 discrimination exposes the weaknesses in current legal protection and
114 underlying ethical framework. To address COVID-19 discrimination, several
115 improvements have been made directly by targeted measures in China. On July 13, 2022,

116 the executive meeting of the Chinese State Council declared that it is strictly forbidden
117 to discriminate against employees recovered from COVID-19, and this discrimination
118 will be penalized. Meanwhile, according to the Chinese laws on infectious disease control
119 and the Employment Promotion Law, employers and human resources service agencies
120 are prohibited from using health and medical information in hiring or promotion.
121 Moreover, COVID-19 test results 30 days before will no longer be presented in the
122 Health Kit (健康宝)—an official smartphone app providing “health passport”, so job
123 employers could no longer ask for "no positive COVID-19 history" in job recruitment.
124 However, there is still a need for effective implementations of these laws and policies.
125 For example, an official channel for logging discrimination complaints is still lacking;
126 inconsistencies and gaps still exist in the coverage and enforcement of current laws and
127 policies.

128 The above laws only apply to protect legal rights. In the longer term, COVID-19 will
129 force us to face ethical challenges for which we have not fully prepared. For the benefit
130 of individuals, it is better to protect the privacy and liberty of COVID-19 patients to avoid
131 discrimination, but should we permit a heightened risk of disease spread? For the benefit
132 of society, it is optimal to pursue the greatest good for the greatest number of people, but
133 should we accept the utilitarianism of reducing mortality as the first principle and
134 sacrifice those who have already lost their health and life from the disease? The sooner
135 we start to face these legal and ethical challenges, the better prepared we will be.

136

137

138 **Weighing the balance between individuals and society in policymaking**

139 In the face of current legal and ethical challenges, we should advocate for proactive
140 modifications in policymaking according to the development of the pandemic. We could
141 weigh the vulnerability of those who suffer the burden of COVID-19 discrimination,
142 while considering the balance with the benefit of sacrificing civil rights to prevent disease
143 spread. In the early phase of the pandemic, the disease only occurs in a minority of the
144 population. The balance between individuals and society is easy to weigh, since the
145 benefit of society far outweighs those of individuals. Therefore, strict quarantine and

146 disease control policies could be adopted. However, with the pandemic spreading to more
147 and more people, the balance will inevitably reach a tipping point, where policymakers
148 need to optimize the trade-offs between the benefits of individuals and society by
149 updating pandemic policies. Going forward, these systemic societal issues required
150 extensive collaboration between scientific and political communities, a collaboration
151 dedicated to incorporating an optimizing balance between individuals and society in
152 policymaking.

153

Journal Pre-proof

154 **Declarations**

155 **Competing interests**

156 The funders had no role in writing this manuscript. This study was conducted in the
157 absence of any commercial or financial relationships that could be construed as a
158 potential conflict of interest.

159

160 **Funding**

161 This project was supported by the National Natural Science Foundation of China
162 (32100739) to Dr. Ming Zheng.

163

164

165 **References**

166

167 [1] R. Liu, S. Nicholas, A. Leng, D. Qian, E. Maitland, J. Wang, The influencing factors of discrimination
168 against recovered Coronavirus disease 2019 (COVID-19) patients in China: a national study, *Hum*
169 *Vaccin Immunother* 18(1) (2022) 1913966.

170 [2] D. Xu, X. Li, R. Laforteza, Employers - stop discrimination against people who've had COVID-
171 19, *Nature* 608(7924) (2022) 667.

172 [3] W. Li, Y. Yang, C.H. Ng, L. Zhang, Q. Zhang, T. Cheung, Y.T. Xiang, Global imperative to combat
173 stigma associated with the coronavirus disease 2019 pandemic, *Psychol Med* 51(11) (2021) 1957-
174 1958.

175 [4] W. Fan, Y. Qian, Y. Jin, Stigma, Perceived Discrimination, and Mental Health during China's
176 COVID-19 Outbreak: A Mixed-Methods Investigation, *J Health Soc Behav* 62(4) (2021) 562-581.

177 [5] X. Xiao, X. Yang, W. Zheng, B. Wang, L. Fu, D. Luo, Y. Hu, N. Ju, H. Xu, Y. Fang, P.S. Fong Chan, Z.
178 Xu, P. Chen, J. He, H. Zhu, H. Tang, D. Huang, Z. Hong, Y. Hao, L. Cai, S. Ye, J. Yuan, F. Xiao, J. Yang,
179 Z. Wang, H. Zou, Depression, anxiety and post-traumatic growth among COVID-19 survivors six-
180 month after discharge, *Eur J Psychotraumatol* 13(1) (2022) 2055294.

181 [6] N. Ju, X. Yang, X. Ma, B. Wang, L. Fu, Y. Hu, D. Luo, X. Xiao, W. Zheng, H. Xu, Y. Fang, P.S.F. Chan,
182 Z. Xu, P. Chen, J. He, H. Zhu, H. Tang, D. Huang, Z. Hong, F. Xiao, F. Sun, Y. Hao, L. Cai, J. Yang, S.
183 Ye, Y.Q. Chen, J. Yuan, Z. Wang, H. Zou, Hospitalization, interpersonal and personal factors of social
184 anxiety among COVID-19 survivors at the six-month follow-up after hospital treatment: the minority
185 stress model, *Eur J Psychotraumatol* 13(1) (2022) 2019980.

186 [7] C.S. McMahan, S. Self, L. Rennert, C. Kalbaugh, D. Kriebel, D. Graves, C. Colby, J.A. Deaver, S.C.
187 Popat, T. Karanfil, D.L. Freedman, COVID-19 wastewater epidemiology: a model to estimate infected
188 populations, *Lancet Planet Health* 5(12) (2021) e874-e881.

189 [8] L. Boggione, G. Meli, F. Poletti, R. Rostagno, R. Moglia, M. Cantone, M. Esposito, C. Scianguetta,
190 B. Domenicale, F. Di Pasquale, S. Borre, Risk factors and incidence of long-COVID syndrome in
191 hospitalized patients: does remdesivir have a protective effect?, *QJM* 114(12) (2022) 865-871.

192 [9] T. Burki, Dynamic zero COVID policy in the fight against COVID, *The Lancet. Respiratory Medicine*
193 (2022).

194 [10] C. Released by National Health, M. National Administration of Traditional Chinese Medicine on,
195 Diagnosis and treatment protocol for COVID-19 patients (Trial Version 9), *Health Care Science* 1(1)
196 (2022) 14-28.

197

198